지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.1
- 수록면
- 32 - 41 (10page)
이용수
초록· 키워드
오류제보하기
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes. Since 2008, three CVOTs that have studied dipeptidyl peptidase-4 (DPP-4) inhibitors and four CVOTs of a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) have been reported. Each of the completed CVOTs showed the noninferiority of respective drugs to placebo for primary CV composite endpoint. Among them, liraglutide and semaglutide showed a reduction of major adverse cardiovascular events. However, the mechanisms for the observed cardiovascular differences between DPP-4 inhibitors and GLP-1RA, and across individual GLP-1RA are not clearly understood. Therefore, this review will summarize the CVOTs of the DPP-4 inhibitors and GLP-1RA, interpretation of cardioprotective results of incretin-based therapy and the possible mechanism of action.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
UK Prospective Diabetes Study (UKPDS) Group / 1998 / Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) / Lancet 352:837~853
American Diabetes Association / 2018 / 6. Glycemic targets: standards of medical care in diabetes-2018 / Diabetes Care 41:S55~S64
Nissen SE / 2007 / Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes / N Engl J Med 356:2457~2471
Scirica BM / 2013 / Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus / N Engl J Med 369:1317~1326
White WB / 2013 / Alogliptin after acute coronary syndrome in patients with type 2 diabetes / N Engl J Med 369:1327~1335
American Diabetes Association / 2018 / 6. Glycemic targets: standards of medical care in diabetes-2018 / Diabetes Care 41:S55~S64
Nissen SE / 2007 / Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes / N Engl J Med 356:2457~2471
Scirica BM / 2013 / Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus / N Engl J Med 369:1317~1326
White WB / 2013 / Alogliptin after acute coronary syndrome in patients with type 2 diabetes / N Engl J Med 369:1327~1335
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
Diabetes and Metabolism Journal
2017 .01
-
Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2016 .01
-
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Annals of Pediatirc Endocrinology & Metabolism
2017 .01
-
Peptidyl and Non-Peptidyl Oral Glucagon-Like Peptide-1 Receptor Agonists
Endocrinology and Metabolism
2021 .01
-
글루카곤양펩티드-1의 췌장 외 효과
대한내과학회지
2015 .01
-
The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea
Diabetes and Metabolism Journal
2015 .01
-
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Endocrinology and Metabolism
2023 .02
-
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study
Diabetes and Metabolism Journal
2023 .01
-
The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
Endocrinology and Metabolism
2019 .01
-
GLP-1 Based Combination Therapy for Obesity and Diabetes
Journal of Obesity & Metabolic Syndrome
2017 .01
-
GLP regulation for medical device
한국실험동물학회 학술발표대회 논문집
2017 .08
-
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study
Diabetes and Metabolism Journal
2024 .03
-
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Endocrinology and Metabolism
2024 .04
-
Insulin/GLP-1 Treatment for Patients with DM
Journal of mucopolysaccharidosis and rare disease
2016 .01
-
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Endocrinology and Metabolism
2019 .01
-
Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function
Annals of Surgical Treatment and Research
2021 .09
-
Effect of Glucagon-like Peptide-1 on the Differentiation of Adipose-derived Stem Cells into Osteoblasts and Adipocytes
대한폐경학회지
2015 .01
-
당뇨병 치료약제와 심혈관 질환
대한내과학회지
2021 .04
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes and Metabolism Journal
2022 .07
-
SGLT2 Inhibitors and GLP-1 Agonists: A Beacon of Hope for Stroke Prevention in Diabetes
Diabetes and Metabolism Journal
2024 .03
이 논문의 저자 정보
최근 본 자료
댓글(0)
0